US PTAB IP Litigation

Home Depot U.S.A., Inc. v.H2 Intellect LLC

· PGR2025-00047

Home Depot has filed a post‑grant review petition seeking cancellation of all 84 claims of H2 Intellect’s U.S. Patent 12,056,736, alleging abstract‑idea ineligibility and obviousness over prior art. The petition relies on §101 and §103 grounds, citing Elliott, Jacob and Sakamoto references.

Samsung Austin Semiconductor, LLC et al. v.Sung, Chien-Min

· IPR2024-00535

Samsung’s IPR against Chien‑Min Sung’s 9,724,802 patent was decided with claims 1‑9 and 12‑21 found unpatentable. The patent owner now petitions the Director to overturn the Board’s findings, arguing errors in the designated‑profile analysis, ignored expert testimony, and improper priority treatment of Sung ’146.

Samsung Austin Semiconductor, LLC et al. v.Sung, Chien-Min

· IPR2024-00534

Samsung’s IPR challenge to a CMP‑pad conditioning patent is contested by the patent owner, who files a Director Review request alleging Board abuse of discretion on anticipation and obviousness grounds. The owner seeks reversal of the final written decision and validation of all 20 claims.

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00384

EndyMed Medical Ltd. and EndyMed Medical Inc. jointly moved to terminate IPR2024-00384 after reaching a settlement with patent owner Serendia, LLC. The Board was asked to end the proceeding before any oral hearing or final decision.

Bruker Spatial Biology, Inc. v.10x Genomics, Inc. et al.

· IPR2024-00526

Bruker Spatial Biology, Inc. and 10x Genomics jointly asked the PTAB to file their settlement agreement as business‑confidential information and keep it separate from the patent file. The request invokes 35 U.S.C. § 317 and related regulations to protect the settlement details.

Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.

· PGR2025-00050

Merck has filed a post‑grant review petition challenging Halozyme’s U.S. Patent 12,077,791 covering modified PH20 hyaluronidase proteins. The petition asserts that the claims are overly broad and lack both written description and enablement under 35 U.S.C. §112(a). Merck seeks institution of the proceeding and cancellation of all claims.

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00384

Serendia requests Director Review to terminate IPR2024-00384, arguing the Board improperly expedited institution of time‑barred petitions despite a pending ITC validity finding. The petition cites the rescinded Fintiv memo and extraordinary circumstances to seek dismissal.

Bruker Spatial Biology, Inc. v.10x Genomics, Inc. et al.

· IPR2024-00526

Bruker Spatial Biology and 10x Genomics have settled their dispute over U.S. Patent 11,542,554, filing a joint motion to terminate the pending IPR. The Board has not issued a final decision, and the parties seek to keep the settlement confidential.

ADC Solutions Auto LLC et al. v.The Noco Company

· IPR2024-00671

The PTAB Director Review email authorizes ADC Solutions Auto LLC to file a 15‑page response to the Patent Owner’s Director Review request in IPR2024‑00671. No new evidence may be submitted and the response must be filed within five business days.

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00384

Jeisys Medical and Serendia have settled their IPR dispute over U.S. Patent 9,320,536 and jointly moved to terminate the proceeding under 35 U.S.C. §317.

DISH Network L.L.C. et al. v.Entropic Communications, LLC

· IPR2024-00462

The USPTO denied DISH Network's request for Director Review of the decision that had previously denied institution of its IPR against Entropic Communications' video‑compression patent.

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00383

EndyMed Medical and Serendia settled their inter partes review disputes over U.S. Patent 9,775,774, leading the PTAB to terminate the proceedings and keep the settlement confidential.

Dexcom, Inc. v.Abbott Diabetes Care Inc.

· IPR2024-00521

Dexcom and Abbott filed a joint request with the PTAB to keep their IPR settlement agreement confidential, invoking statutory provisions for business‑confidential treatment.

patent instituted

Samsung Austin Semiconductor, LLC et al. v.Sung, Chien-Min

· IPR2024-00535

The PTAB sent an email directing Samsung Austin Semiconductor to file a limited 15‑page response to a Director Review request for IPR2024‑00534 and IPR2024‑00535, prohibiting new evidence and additional briefings.

Nichia Corporation v.BX LED LLC

· IPR2024-00542

Nichia Corp. and BX LED LLC settled their dispute over U.S. Patent 8,567,988 B2, leading the PTAB to terminate the IPR before institution. The settlement agreement was ordered kept confidential.

patent instituted

Mito Red Light, Inc. v.Joovv, Inc.

· IPR2024-00621

Mito Red Light and Joovv jointly request that their settlement agreement be treated as Confidential Business Information in the IPR.

Arm Limited v.ICPillar LLC

· IPR2024-00566

The USPTO denied Arm Limited's request for Director Review of the institution decision in IPR2024-00566 concerning patent 9,367,657. The original institution decision remains in effect.

SAP America, Inc. v.ISIX IP LLC

· IPR2024-00615

SAP America and ISIX IP settled their dispute over a 1999 ERP‑related patent and jointly moved to terminate the inter partes review. The Board has not yet decided any merits, allowing termination under 35 U.S.C. § 317(a).

Samsung Austin Semiconductor, LLC et al. v.Sung, Chien-Min

· IPR2024-00534

The USPTO Director denied Samsung’s request for a review of the Final Written Decision in IPR2024‑00534 concerning patent 9,138,862. The order affirms the earlier IPR outcome and provides no further relief.

Nintendo Co., Ltd. et al. v.American GNC Corporation

· IPR2024-00667

The PTAB denied Nintendo’s petitions for Director Review of the final written decisions in two IPRs against American GNC’s patents, leaving the original rulings unchanged.

Dexcom, Inc. v.Abbott Diabetes Care Inc.

· IPR2024-00521

Dexcom and Abbott Diabetes Care settled their IPR dispute over U.S. Patent 11,298,056 covering continuous glucose monitoring technology. The parties filed a joint motion to terminate, and the Board granted termination without a final written decision.

Amazon.com, Inc. et al. v.Nokia Technologies Oy

· IPR2024-00626

Amazon and Nokia have settled their dispute over U.S. Patent 11,805,267 and jointly moved to terminate the inter partes review. The motion cites statutory authority and public‑policy benefits of settlement.

Databricks, Inc. v.R2 Solutions LLC

· IPR2024-00659

The PTAB denied Databricks' request for Director Review of the earlier decision that refused to institute its IPR against R2 Solutions' data‑processing patent. The Director recused herself, and the Deputy Under Secretary upheld the denial.